Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · June 05, 2024

Effect of SGLT2 Inhibitors on Heart Failure Outcomes and Cardiovascular Death Across the Cardiometabolic Disease Spectrum

The Lancet Diabetes & Endocrinology


Additional Info

The Lancet Diabetes & Endocrinology
Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis
Lancet Diabetes Endocrinol 2024 May 17;[EPub Ahead of Print], MS Usman, DL Bhatt, I Hameed, SD Anker, AYY Cheng, AF Hernandez, WS Jones, MS Khan, MC Petrie, JA Udell, T Friede, J Butler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading